rs587776438
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PS4_ModeratePM6PP3PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The m.10254G>A (p.D66N) variant in MT-ND3 has been reported in at least five unrelated individuals with primary mitochondrial disease. Three individuals had features consistent with Leigh syndrome, with onset in or around the first year of life, and two individuals had features of optic neuropathy (PS4_moderate; PMIDs: 20202874, 27290639, 26238931, 36913248). There are at least two de novo occurrences reported in the literature (PM6; PMIDs: 20202874, 27290639). The computational predictors APOGEE1 and APOGEE2 give a consensus rating of pathogenic with raw scores of 0.56 and 0.925, respectively (Min=0, Max=1), which predict a damaging effect on gene function (PP3). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on October 23, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID:32906214): PS4_moderate, PM6, PM2_supporting, PP3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA345916/MONDO:0044970/015
Frequency
Consequence
ENST00000361227.2 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ND3 | unassigned_transcript_4808 | c.196G>A | p.Asp66Asn | missense_variant | Exon 1 of 1 | |||
| ND4L | unassigned_transcript_4810 | c.-216G>A | upstream_gene_variant | |||||
| TRNR | unassigned_transcript_4809 | c.-151G>A | upstream_gene_variant | |||||
| TRNG | unassigned_transcript_4807 | c.*196G>A | downstream_gene_variant |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MT-ND3 | ENST00000361227.2 | c.196G>A | p.Asp66Asn | missense_variant | Exon 1 of 1 | 6 | ENSP00000355206.2 | |||
| MT-ND4L | ENST00000361335.1 | c.-216G>A | upstream_gene_variant | 6 | ENSP00000354728.1 | |||||
| MT-TR | ENST00000387439.1 | n.-151G>A | upstream_gene_variant | 6 | ||||||
| MT-TG | ENST00000387429.1 | n.*196G>A | downstream_gene_variant | 6 |
Frequencies
Mitomap
ClinVar
Submissions by phenotype
Mitochondrial disease Pathogenic:1
The m.10254G>A (p.D66N) variant in MT-ND3 has been reported in at least five unrelated individuals with primary mitochondrial disease. Three individuals had features consistent with Leigh syndrome, with onset in or around the first year of life, and two individuals had features of optic neuropathy (PS4_moderate; PMIDs: 20202874, 27290639, 26238931, 36913248). There are at least two de novo occurrences reported in the literature (PM6; PMIDs: 20202874, 27290639). The computational predictors APOGEE1 and APOGEE2 give a consensus rating of pathogenic with raw scores of 0.56 and 0.925, respectively (Min=0, Max=1), which predict a damaging effect on gene function (PP3). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on October 23, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4_moderate, PM6, PM2_supporting, PP3. -
Leigh syndrome Other:1
- -
Computational scores
Source: